FNDC3B and brain neoplasm: To specifically verify the expression of FNDC3B in brain pathologies, we compared expression levels across 2510 samples, which included Alzheimer’s dementia, major depressive disorder (MDD), epilepsy, Parkinson’s disease, and brain tumors of varying grades and molecular specifications (Figure 1b, Table 2).